Cutaneous T-cell Lymphoma

• FDA approval · 2013-07-22
  FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)

  FDA approved a supplemental application for TARGRETIN (bexarotene) submitted by Bausch Health US, LLC.

• FDA approval · 2013-04-24
  FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)

  The FDA approved a supplemental application for Zolinza (vorinostat) filed by Merck. The action updates the labeling and may reflect changes…

• FDA approval · 2012-01-06
  FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)

  The FDA approved a supplemental application for TARGRETIN (bexarotene) submitted by Bausch Health US, LLC.

• FDA approval · 2011-11-14
  FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)

  FDA approved a supplemental application for Zolinza (vorinostat) by Merck Sharp & Dohme LLC.

• FDA approval · 2011-04-12
  FDA Approved: ISTODAX — Supplemental Application (Celgene Corporation)

  The FDA approved a supplemental application for Istodax (romidepsin) submitted by Celgene Corporation.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2011-04-08
  FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)

  The FDA approved a supplemental application for TARGRETIN (bexarotene) filed by Bausch Health US, LLC.

• FDA approval · 2009-11-05
  FDA Approved: ISTODAX — Original Application (Celgene Corporation)

  The FDA granted original approval for ISTODAX (romidepsin) to Celgene. The approval covered treatment for cutaneous T-cell lymphoma, includi…

• FDA approval · 2009-09-23
  FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)

  FDA approved a supplemental application for ZOLINZA (vorinostat) submitted by Merck Sharp & Dohme LLC.

• FDA approval · 2008-07-22
  FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)

  The FDA approved a supplemental application for Zolinza (vorinostat) by Merck Sharp & Dohme LLC to update/expand its labeling.

• FDA approval · 2006-10-06
  FDA Approved: ZOLINZA — Original Application (Merck Sharp & Dohme LLC)

  The FDA approved Zolinza (vorinostat) under original NDA for cutaneous T-cell lymphoma, marking the first approval of this histone deacetyla…